HELIUS Stock Skyrockets 217% on $92.8M ATM Filing and $9.1M Offering

Introduction

HELIUS Medical Technologies, Inc. (NASDAQ: HSDT) is a neurotechnology company developing non-implantable platform devices to treat neurologic deficits by promoting neuroplasticity. Its primary product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical stimulation to the tongue’s surface in conjunction with supervised therapeutic activity, targeting improvements in balance and gait in patients with conditions such as multiple sclerosis (MS), traumatic brain injury (TBI), and stroke.

Corporate Structure

Headquartered in Newtown, Pennsylvania, HELIUS Medical Technologies operates as a public company under the ticker HSDT on the NASDAQ exchange. According to its LinkedIn profile, the organization employs between 11 and 50 staff in various functions, including manufacturing, clinical development, and supply chain management. Key leadership roles encompass clinical, regulatory, and manufacturing expertise, reflecting a structure aligned with medical-device development and commercialization.

Neurotechnology by David Matos

Recent Developments and News

• June 6, 2025: HELIUS completed a public offering of 2,768,600 Class A common shares and warrants at $3.27 per unit, raising approximately $9.1 million. Legal counsel Honigman advised on the transaction.
• September 12, 2025: The last reported sale price on NASDAQ was $7.56 per share.
• September 15, 2025: HELIUS filed a prospectus supplement (Rule 424(b)(5)) to offer up to $92.8 million of Class A common stock under an at-the-market sales agreement with Clear Street LLC and Maxim Group LLC. The filing allows for ongoing share issuance with agent compensation up to 3% of gross proceeds. On the same date, the company submitted an 8-K filing, reporting current items 1.01, 3.02, 7.01, 8.01, and 9.01.
• September 15, 2025: Shares closed at $24.03, reflecting a substantial increase of 217.91% on a trading volume of 3,244,645 shares.
• Fall 2025: U.S. Veterans Magazine featured a patient story detailing PoNS Therapy’s effects on gait improvement among individuals with MS.

Financial and Strategic Analysis

HELIUS has engaged in equity financing to support its commercialization and research and development (R&D) efforts. The June 2025 offering generated $9.1 million, while the September 2025 prospectus seeks to raise up to $92.8 million through at-the-market transactions. The increase in stock price on September 15, 2025, suggests investor interest, likely influenced by expanding indications for the PoNS device and patient adoption. The sales agreement structure allows HELIUS to access capital markets as needed, with sales agents compensated based on a percentage of gross proceeds, aligning their incentives with the company's fundraising goals.

Market Position and Industry Context

HELIUS operates within the neurorehabilitation segment of the medical-device industry, which is characterized by the rising demand for non-invasive therapies that address functional neurological deficits. The PoNS® device has received FDA approval in the U.S. for the short-term treatment of gait deficit associated with mild-to-moderate MS and has been authorized in Canada and Australia for addressing balance and gait deficits related to TBI, MS, and stroke. HELIUS’s portable neuromodulation technology distinguishes it from implantable devices and pharmaceutical alternatives, positioning the company to potentially increase its market share as rehabilitative care increasingly focuses on neuroplasticity-based interventions.

tl;dr

On September 15, 2025, HELIUS Medical Technologies’ shares increased by 217.91% to $24.03 on a trading volume of approximately 3.24 million shares. Earlier, on June 6, 2025, the company raised $9.1 million through a public offering, and on September 15, 2025, filed to sell up to $92.8 million in stock via at-the-market agreements. With approvals for the PoNS® device in the U.S., Canada, and Australia, HELIUS aims to leverage its financing framework to potentially enhance market penetration in neurorehabilitation.